Blood Reviews
Volume 24, Issue 2 , Pages 63-68 , March 2010

Hemostasis in neonates and children: Pitfalls and dilemmas

  • Paul Monagle

      Affiliations

    • Department of Clinical Haematology, Department of Paediatrics, University of Melbourne, Royal Children’s Hospital, Flemington Rd. Parkville, Victoria 3052, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 3 9345 5914; fax: +61 3 9349 1819.
    • ,
  • Vera Ignjatovic

      Affiliations

    • Haematology Research, Murdoch Children’s Research Institute, Royal Children’s Hospital, Flemington Rd. Parkville, Victoria 3052, Australia
    • Tel.: +61 3 9936 6520; fax: +61 3 8341 6212.
    • ,
  • Helen Savoia

      Affiliations

    • Laboratory Services, Royal Children’s Hospital, Flemington Rd. Parkville, Victoria 3052, Australia
    • Tel.: +61 3 9345 5914; fax: +61 3 9349 1819.

References 

  1. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood. 1988;72:1651–1657
  2. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70:165–172
  3. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998–2005
  4. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990;12:95–104
  5. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95:362–372
  6. Chan KL, Summerhayes RG, Ignjatovic V, Horton SB, Monagle PT. Reference values for kaolin-activated thromboelastography in healthy children. Anesth Analg. 2007;105:1610–1613[table of contents]
  7. Monagle P, Hagstrom J. Developmental haemostasis. In: Polin  editors. Fetal and neonatal physiology. 3rd ed.. Elsevier: St. Louis; 2003;p. 1435–1447
  8. Witt I, Muller H. Phosphorus and hexose content of human foetal fibrinogen. Biochim Biophys Acta. 1970;221:402–404
  9. Hamulyak K, Nieuwenhuizen W, Devilee PP, Hemker HC. Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns. Thromb Res. 1983;32:301–310
  10. Witt I, Muller H, Kunzer W. Evidence for the existence of foetal fibrinogen. Thromb Diath Haemorrh. 1969;22:101–109
  11. Miller BE, Tosone SR, Guzzetta NA, Miller JLKK, Brosius KK. Fibrinogen in children undergoing cardiac surgery: is it effective?. Anesth Analg. 2004;99:1341–1346
  12. Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood. 1983;61:1196–1202
  13. Dang CV, Shin CK, Bell WR, Nagaswami C, Weisel JW. Fibrinogen sialic acid residues are low affinity calcium binding sites that influence fibrin assembly. J Biol Chem. 1989;264:15104–15108
  14. Al Dieri R, Peyvandi F, Santagostino E, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Throm Haemost. 2002;88:576–582
  15. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost. 1995;74:134–138
  16. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15
  17. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost. 1993;70:617–624
  18. Ignjatovic V, Greenway A, Summerhayes R, Monagle P. Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis. Br J Haematol. 2007;138:366–368
  19. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med. 2001;135:98–107
  20. Biss TT, Brandao LR, Kahr WH, Chan AK, Williams S. Clinical probability score and D-dimer estimation lack utility in the diagnosis of childhood pulmonary embolism. J Thromb Haemost. 2009;7:1633–1638
  21. Bauman ME, Belletrutti MJ, Bajzar L, et al. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels. Thromb Haemost. 2009;101:86–92
  22. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr. 2000;136:439–445
  23. Kuhle S, Massicotte P, Dinyari M, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost. 2005;94:1164–1171
  24. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128:313–318
  25. Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res. 2003;109:101–108
  26. Ignjatovic V, Furmedge J, Newall F, et al. Age-related differences in heparin response. Thromb Res. 2006;118:741–745
  27. Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost. 1994;72:836–842
  28. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324–327
  29. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109–1114
  30. Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost. 2006;4:2280–2282
  31. Newall F, Ignjatovic V, Summerhayes R, et al. In vivo age dependency of unfractionated heparin in infants and children. Thromb Res. 2009;123:710–714
  32. Ignjatovic V, Summerhayes R, Gan A, et al. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate?. Thromb Res. 2007;120:347–351
  33. Schedin-Weiss S, Richard B, Hjelm R, Olson ST. Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence. Biochemistry. 2008;47:13610–13619
  34. Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev. 2007;CD006652
  35. Adcock DM, Fink LM, Marlar RA, Cavallo F, Zangari M. The hemostatic system and malignancy. Clin Lymph Myeloma. 2008;8:230–236
  36. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost. 2004;30:5–20
  37. Niessen RW, Lamping RJ, Peters M, Lamers WH, Sturk A. Fetal and neonatal development of antithrombin III plasma activity and liver messenger RNA levels in sheep. Pediatr Res. 1996;39:685–691
  38. Schmidt B, Gillie P, Mitchell L, Andrew M, Caco C, Roberts R. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med. 1998;158:470–476

PII: S0268-960X(09)00081-2

doi: 10.1016/j.blre.2009.12.001

Blood Reviews
Volume 24, Issue 2 , Pages 63-68 , March 2010

Article Tools